Abstract
The clinical use, safety and effectiveness of ceftolozane/tazobactam among 13 patients 3 months to 19 years of age infected with multidrug-resistant Pseudomonas aeruginosa are described. All but one patient achieved clinical cure after initial treatment. Adverse drug events attributed to treatment included transaminitis and neutropenia which occurred in 2 patients and resolved upon dose reduction.
Original language | English |
---|---|
Pages (from-to) | 419-420 |
Number of pages | 2 |
Journal | Pediatric Infectious Disease Journal |
DOIs | |
State | Accepted/In press - 2020 |
Keywords
- Ceftolozane/tazobactam
- Multidrug-resistant
- Pseudomonas aeruginosa